因美纳管理团队

Jacob Thaysen, PhD is Chief Executive Officer of Illumina. Prior to joining the company in 2023, Thaysen served as president of the Life Sciences and Applied Markets Group and Diagnostic and Genomics Group at Agilent; corporate vice president of R&D at Dako; and management consultant at Copenhagen Consultancy Company (now Bain & Co).

Early in his career, he was founder and chief technology officer of Cantion, a research and defense application development company based in Denmark. Thaysen is Chairman of the ALDA Board (Analytical, Life Science and Diagnostic Association) and is a San Diego Chapter member of the American Cancer Society’s CEOs Against Cancer.

Thaysen holds an MSc and PhD in physics from the Technical University of Denmark.

Steve Barnard博士是因美纳的首席技术官。他负责领导因美纳在工程、耗材、应用、用户设计、软件、信息学、人工智能、科学事务和全球先进科学领域的研究与产品开发团队。这些团队是因美纳的创新引擎，在新一代测序平台和应用方面提供出众的产品，加速科学突破以及基因组学成果向临床转化。

Barnard博士于1998年加入Illumina，成为该公司的第一位科学家和第四位员工，在其杰出的25年任期内在Illumina的研发组织担任过各种领导职务。作为研究和技术开发层面的中流砥柱，Barnard为因美纳基础科学技术迈向成熟做出了重大贡献，包括合成化学、蛋白质工程、表面科学、检测研究和纳米制造。他在全球拥有100多项专利，并发表在多个行业领先的科学期刊上，例如 分析化学、自然、科学和基因组研究等。

Barnard博士在推进因美纳业界出色产品的发展方面发挥了不可或缺的作用，包括推出革命性的NovaSeq X系列。他对Illumina核心技术的深刻理解正在提高研发生产力和效率，并推动股东的价值。

Todd Christian is Head of Services, Arrays, and Genomics Access (SAGA) at Illumina, where he is responsible for the go-to-market strategy and commercialization of arrays, pharma and clinical diagnostics partnerships, Population Genomics, Services and Support, and Illumina Lab Services.

Before joining Illumina, Christian was vice president and general manager of the cell analysis division at Agilent Technologies, Inc. During his time there, he was an integral part of the company’s multi-year growth strategy to expand its position in cell analysis and other high-growth segments of the life sciences, biopharma and diagnostics markets to serve new and existing customers.

Christian is a distinguished leader in the life sciences market, with more than 25 years of experience in the industry. Before joining Agilent, he spent a number of years at both large and small organizations in the life sciences space, including Becton Dickinson, Applied Bioscience, and Guava Technologies.

He holds a Bachelor of Arts from Hamilton College and a variety of executive certificate programs in marketing, program management, and operations. He has recently served on a variety of non-profit boards focused on funding youth education and underserved communities, and actively volunteers with Habitat for Humanity.

Everett Cunningham is Illumina’s Chief Commercial Officer (CCO), responsible for building, guiding, and managing the company’s global commercial organization and commercial strategy. 

Cunningham joined the company in June 2024 and has more than 20 years of extensive commercial experience across healthcare tech, life sciences and pharmaceutical industries. Most recently, he served as Chief Commercial Officer at Exact Sciences, where he oversaw the company’s marketing, sales and customer service functions. Prior to Exact Sciences, he held various senior leadership roles at Quest Diagnostics, GE Healthcare, and Pfizer where he spent 21 years in various senior leadership roles.  

Cunningham has a degree in economics from Northwestern University. He is a member of the Board of Directors for Visby Medical and Arvinas.

As interim General Counsel and Secretary, Scott Davies has worldwide responsibility for all legal and intellectual property matters and regulatory and government affairs. He also serves as Illumina's code of ethics compliance officer.

Prior to his appointment as interim General Counsel and Secretary, Davies served as Illumina’s Vice President, Legal – Chief Corporate Counsel and Assistant Secretary. Davies joined Illumina in 2009 as its first corporate-focused attorney and has managed all of Illumina’s significant corporate legal matters and transactions since that time. While taking on positions of increasing responsibility, Davies developed and led a global corporate and commercial legal team and has worked closely with Illumina’s senior executive team and board of directors on a wide range of legal matters across the spectrum of Illumina’s global business operations.

Prior to joining Illumina, Davies was a corporate transactions (M&A), securities, and finance attorney for 12 years, including 10 years with Gibson, Dunn & Crutcher LLP, a leading international law firm, and two years with Allen & Overy, a leading UK-based global law firm, resident in its London office.

Davies received a J.D. from Cornell Law School and a B.A. from Brigham Young University.

As Chief Financial Officer (CFO), Ankur Dhingra is responsible for Illumina’s accounting, financial planning and analysis, internal audit, investor relations, tax, and treasury functions.

Prior to joining Illumina, Dhingra served as CFO at Summit Therapeutics – a California-based biopharmaceutical oncology company. He was previously CFO at CareDx, Inc, a molecular diagnostics company focused on the transplant patient journey. Dhingra spent 18 years at Agilent Technologies in a variety of financial and operational leadership roles, including Vice President of Investor Relations and Group CFO for the Life Sciences and Applied Markets Group (LSAG), which consists of Agilent's market leading analytical instrument portfolio, informatics, and cell analysis franchise.

Mr. Dhingra is a Chartered Accountant from The Institute of Chartered Accountants of India.

Pat Leckman是Illumina的首席人力官，负责公司人力资源战略的各个方面。Leckman在领导员工转型、推动业务增长和创建高影响力团队方面有着良好的业绩记录。

此前，她曾在Watson Wyatt、NVIDIA、Cisco和Perot Systems等动态组织工作。在她担任Illumina人力资源领导团队期间，她改变了薪酬、福利和人事技术职能。她领导的国际团队设计、签约并实施协议和合资企业。在她的职业生涯中，她帮助客户重新设计业务流程、评估供应商、外包和过渡管理。

Leckman拥有伦敦商学院的工商管理硕士学位和斯坦福大学的通信学士学位。

Kevin Pegels是Illumina的全球运营主管，负责公司的全球运营。他管理的部门包括制造、供应链、生命周期管理、信息技术及全球设施和不动产团队，这些团队致力于确保生产高质量的产品，提升客户满意度。

在加入Illumina前，Kevin曾在Bayer Healthcare、The Clorox Company和Levi Strauss担任了超过20年的供应链和运营部门高级领导。此外，他还曾在德勤咨询公司担任供应链、运营策略和流程改进方面的顾问。

Kevin目前在Bio Supply Management Alliance（BSMA）的咨询委员会工作，将加入圣迭戈地区EDC的委员会。他拥有康奈尔大学化学工程学士学位以及哈佛商学院工商管理硕士学位。

Carissa Rollins是Illumina的首席信息官，负责领导全球信息系统的所有战略、运营、风险和合规性、基础设施、企业架构、网络安全、员工和面向业务的应用。

在加入Illumina之前，Rollins是UnitedHealthcare的首席信息官。她负责战略、路线图和技术投资，以支持UnitedHealthcare的商业、医疗保险和退休以及政府项目技术业务组合。在加入UnitedHealthcare之前，Rollins曾在Kohl’s Corporation、Manpower Global和Miller-Coors的Gander Mountain担任高管和高级职务。

Rollins曾在明尼阿波利斯YWCA董事会任职，目前担任董事会主席。她还在Grand Canyon Conservancy董事会和Owens & Minor董事会任职。

Rollins拥有管理信息系统学士学位和马凯特大学工商管理硕士学位。

Salli Schwartz担任投资人关系副总裁，领导所有投资人战略和活动，包括季度收益发布和电话会议、投资人报告以及日常交流。

Schwartz在加入Illumina之前曾在MSCI担任投资人关系主管及财务总监，具备深厚的专业知识。在MSCI任职期间，她管理与股权和债务投资人、卖方分析者、评级机构和合作银行的关系，并负责公司融资、现金管理和资本配置活动。Schwartz还曾担任MSCI企业责任委员会、企业风险监管委员会和投资委员会的成员。

而在加入MSCI前，Schwartz在Moody’s Corporation供职超过12年，最后担任全球战略资本管理主管及财务主管。她此前担任过财务主管、投资人关系及沟通全球主管，以及Moody’s Corporation发展团队成员。

Schwartz还在Citigroup Inc.担任企业战略、企业资金和FP&A职位，并在Legg Mason担任投资银行和商业银行职位。她此前担任美国国立学术基金会（NAF）董事长兼审计委员会主席，NAF是一家非营利性机构，构建了一张由全美教育、商业和社区领导人组成的网络，共同确保高中生为大学、职业和未来做好准备。

Schwartz拥有康奈尔大学工商管理硕士学位和宾夕法尼亚大学文学学士学位，两者都具有优异的成绩。

Jakob Wedel is Chief Strategy and Corporate Development Officer at Illumina, leading corporate strategy, partnerships, alliances, and acquisitions. With more than 25 years in top-tier strategy consulting focused on the life science and technology sector, Mr. Wedel brings a wealth of expertise in driving growth and innovation to the company.

Prior to joining Illumina, Wedel was a Senior Partner at Ernst and Young's strategy practice, EY Parthenon, where he played a key role in the global expansion of its life science strategy practice. His leadership in the global life science practice provided him with deep insights into the dynamics of the life science tools, clinical diagnostics and biopharma sectors, and positioned him as a trusted advisor for global industry executives.

Wedel spent more than 20 years at renowned consulting firms McKinsey and Bain & Co. serving life science, diagnostics and pharmaceutical clients in the US and Europe. He co-founded the Nordic strategy firm Qvartz, which grew to 450 professionals before being acquired by Bain.

Wedel attended Aarhus University in Denmark and earned a Master of Science in International Marketing & Management from Copenhagen Business School.

Jenny Zheng是Illumina大中华区区域负责人，负责推动公司在大中华区的战略和发展，推动这一关键市场的持续突破，并为公司改善人类健康的长期使命做出贡献。

Zheng女士在医疗保健和制药领域拥有超过25年的国际经验。在加入Illumina之前，她曾担任西安杨森制药有限公司的董事长兼总裁。在多次领导期间，她领导了各个国家和地区市场的团队，实现了两位数的增长，管理了多个战略项目的成功运营，并培养了一支高性能、包容性和目标驱动的管理团队。

Zheng女士被评为2022年福布斯中国十大女商人，2022年财富中国最有影响力的女性。她拥有上海交通大学的工程学学士学位和芝加哥大学布斯商学院的工商管理硕士学位。